News Daily News Little Pre- and Postmarket Testing for Most Recalled CV Devices Michael O'Riordan September 16, 2024
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022